Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL
Clinical trial NCT06658925 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06658925
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-01
- Primary completion
- 2027-08-31
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.